Insider · CIK 0001222357

MARIANI PETER J

Reports to the SEC for 4 companies · PRINCETON, NJ

sec.gov

Transactions

Companies

Filings

CIK

0001222357

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-15	CTSOCytosorbents CorpP Purchase	Chief Financial Officer	PPurchase	+100K sh	$0.44	+$44K	638,113
2025-08-08	CTSOCytosorbents CorpA Award	Chief Financial Officer	AAward	+71.5K sh	—	—	538,113
2025-08-08	CTSOCytosorbents Corp · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+90K sh	—	—	90,000
2025-02-24	CTSOCytosorbents CorpO Exercise Out-of-Money	Chief Financial Officer	OExercise Out-of-Money	+32.6K sh	$1.13	+$36.9K	466,613
2025-02-24	CTSOCytosorbents Corp · Series A Right Warrants (right to buy)O Exercise Out-of-Money	Chief Financial Officer	OExercise Out-of-Money	−32.6K sh	$1.13	−$36.9K	0
2025-01-17	CTSOCytosorbents CorpX Exercise of In-Money	Chief Financial Officer	XExercise of In-Money	+32.6K sh	$1.00	+$32.6K	433,988
2025-01-17	CTSOCytosorbents Corp · Subscription Rights (right to buy)X Exercise of In-Money	Chief Financial Officer	XExercise of In-Money	−32.6K sh	—	—	0
2025-01-17	CTSOCytosorbents Corp · Series A Right WarrantsJ Other	Chief Financial Officer	JOther	+32.6K sh	—	—	32,625
2025-01-17	CTSOCytosorbents Corp · Series B Right WarrantsJ Other	Chief Financial Officer	JOther	+32.6K sh	—	—	32,625
2024-12-13	CTSOCytosorbents CorpP Purchase	Chief Financial Officer	PPurchase	+20K sh	$0.96	+$19.3K	401,363
2024-12-12	CTSOCytosorbents CorpP Purchase	Chief Financial Officer	PPurchase	+20K sh	$0.89	+$17.9K	381,363
2024-12-11	CTSOCytosorbents CorpP Purchase	Chief Financial Officer	PPurchase	+11.4K sh	$0.89	+$10.1K	361,363
2024-08-14	CTSOCytosorbents CorpA Award	Chief Financial Officer	AAward	+110K sh	—	—	110,000
2024-08-14	CTSOCytosorbents CorpA Award	Chief Financial Officer	AAward	+65K sh	—	—	175,000
2024-08-14	CTSOCytosorbents CorpA Award	Chief Financial Officer	AAward	+175K sh	—	—	350,000
2024-08-14	CTSOCytosorbents Corp · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+80K sh	—	—	80,000
2024-08-14	CTSOCytosorbents Corp · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+215K sh	—	—	215,000
2023-12-11	AXGNAxogen, Inc.S Sale	EVP & Chief Financial Officer	SSale	−1,410 sh	$7.52	−$10.6K	74,693
2023-12-11	AXGNAxogen, Inc.S Sale	EVP & Chief Financial Officer	SSale	−3,120 sh	$7.51	−$23.4K	71,573
2023-12-11	AXGNAxogen, Inc.S Sale	EVP & Chief Financial Officer	SSale	−7,970 sh	$7.50	−$59.8K	63,603
2023-10-13	AXGNAxogen, Inc.D Disposition to Issuer	EVP & Chief Financial Officer	DDisposition to Issuer	−3,263 sh	$4.04	−$13.2K	76,103
2023-07-18	AXGNAxogen, Inc.A Award	EVP & Chief Financial Officer	AAward	+3,709 sh	—	—	79,366
2023-03-16	AXGNAxogen, Inc.M Exercise/Conversion	EVP & Chief Financial Officer	MExercise/Conversion	+5,500 sh	—	—	67,445
2023-03-16	AXGNAxogen, Inc.F Tax Payment	EVP & Chief Financial Officer	FTax Payment	−1,866 sh	$8.27	−$15.4K	65,579
2023-03-16	AXGNAxogen, Inc.M Exercise/Conversion	EVP & Chief Financial Officer	MExercise/Conversion	+15.3K sh	—	—	80,829
2023-03-16	AXGNAxogen, Inc.F Tax Payment	EVP & Chief Financial Officer	FTax Payment	−5,172 sh	$8.27	−$42.8K	75,657
2023-03-16	AXGNAxogen, Inc. · Restricted Stock UnitsM Exercise/Conversion	EVP & Chief Financial Officer	MExercise/Conversion	−5,500 sh	—	—	5,500
2023-03-16	AXGNAxogen, Inc. · Restricted Stock UnitsM Exercise/Conversion	EVP & Chief Financial Officer	MExercise/Conversion	−15.3K sh	—	—	15,250
2023-03-16	AXGNAxogen, Inc. · Employee Stock Option (right to purchase)A Award	EVP & Chief Financial Officer	AAward	+94.5K sh	—	—	94,500
2023-03-16	AXGNAxogen, Inc. · Restricted Stock UnitsA Award	EVP & Chief Financial Officer	AAward	+65.6K sh	—	—	65,600
2023-02-01	AXGNAxogen, Inc.M Exercise/Conversion	EVP & Chief Financial Officer	MExercise/Conversion	+20.9K sh	$5.04	+$106K	76,495
2023-02-01	AXGNAxogen, Inc.S Sale	EVP & Chief Financial Officer	SSale	−14.6K sh	$9.36	−$136K	61,945
2023-02-01	AXGNAxogen, Inc. · Employee Stock Option (right to purchase)M Exercise/Conversion	EVP & Chief Financial Officer	MExercise/Conversion	−20.9K sh	—	—	0
2023-01-31	AXGNAxogen, Inc.M Exercise/Conversion	EVP & Chief Financial Officer	MExercise/Conversion	+20.9K sh	$5.04	+$106K	69,875
2023-01-31	AXGNAxogen, Inc.S Sale	EVP & Chief Financial Officer	SSale	−14.3K sh	$9.55	−$137K	55,555
2023-01-31	AXGNAxogen, Inc. · Employee Stock Option (right to purchase)M Exercise/Conversion	EVP & Chief Financial Officer	MExercise/Conversion	−20.9K sh	—	—	20,940
2023-01-30	AXGNAxogen, Inc.M Exercise/Conversion	EVP & Chief Financial Officer	MExercise/Conversion	+20.9K sh	$5.04	+$106K	63,047
2023-01-30	AXGNAxogen, Inc.S Sale	EVP & Chief Financial Officer	SSale	−14.1K sh	$9.69	−$137K	48,936
2023-01-30	AXGNAxogen, Inc. · Employee Stock Option (right to purchase)M Exercise/Conversion	EVP & Chief Financial Officer	MExercise/Conversion	−20.9K sh	—	—	41,879
2023-01-27	AXGNAxogen, Inc.M Exercise/Conversion	EVP & Chief Financial Officer	MExercise/Conversion	+20.9K sh	$5.04	+$106K	63,048
2023-01-27	AXGNAxogen, Inc.S Sale	EVP & Chief Financial Officer	SSale	−20.9K sh	$10.16	−$213K	42,108
2023-01-27	AXGNAxogen, Inc. · Employee Stock Option (right to purchase)M Exercise/Conversion	EVP & Chief Financial Officer	MExercise/Conversion	−20.9K sh	—	—	62,818
2023-01-26	AXGNAxogen, Inc.M Exercise/Conversion	EVP & Chief Financial Officer	MExercise/Conversion	+20.9K sh	$5.04	+$106K	63,047
2023-01-26	AXGNAxogen, Inc.S Sale	EVP & Chief Financial Officer	SSale	−20.9K sh	$9.90	−$207K	42,108
2023-01-26	AXGNAxogen, Inc. · Employee Stock Option (right to purchase)M Exercise/Conversion	EVP & Chief Financial Officer	MExercise/Conversion	−20.9K sh	—	—	83,758
2023-01-25	AXGNAxogen, Inc.M Exercise/Conversion	EVP & Chief Financial Officer	MExercise/Conversion	+20.9K sh	$5.04	+$106K	63,047
2023-01-25	AXGNAxogen, Inc.S Sale	EVP & Chief Financial Officer	SSale	−20.9K sh	$10.23	−$214K	42,108
2023-01-25	AXGNAxogen, Inc. · Employee Stock Option (right to purchase)M Exercise/Conversion	EVP & Chief Financial Officer	MExercise/Conversion	−20.9K sh	—	—	104,697
2022-12-27	AXGNAxogen, Inc.M Exercise/Conversion	EVP & Chief Financial Officer	MExercise/Conversion	+2,625 sh	—	—	42,757
2022-12-27	AXGNAxogen, Inc.F Tax Payment	EVP & Chief Financial Officer	FTax Payment	−649 sh	$9.44	−$6,126.56	42,108

Recent filings

Accepted (ET)
Jun 164
MARIANI PETER J0001104659-26-074291
SEC(opens sec.gov)
Aug 84
MARIANI PETER J0001104659-25-075794
SEC(opens sec.gov)
Feb 264
MARIANI PETER J0001104659-25-017620
SEC(opens sec.gov)
Jan 224
MARIANI PETER J0001104659-25-005352
SEC(opens sec.gov)
Dec 164
MARIANI PETER J0001104659-24-128667
SEC(opens sec.gov)
Dec 134
MARIANI PETER J0001104659-24-128223
SEC(opens sec.gov)
Aug 164
MARIANI PETER J0001104659-24-090596
SEC(opens sec.gov)
Dec 134
MARIANI PETER J0000805928-23-000153
SEC(opens sec.gov)

Companies

Address

C/O CYTOSORBENTS CORPORATION 305 COLLEGE ROAD EAST

PRINCETON, NJ, 08540